IFNG and melanoma: The study demonstrated that activation of IFN-γ-responsive genes, which are involved in processes such as antigen presentation, cytotoxic T cell responses, and chemokine expression, was critical for achieving clinical effectiveness in patients across multiple cancer types, including melanoma, bladder, gastric, ovarian, and colorectal cancer [33].